Organogenesis Holdings Inc. (ORGO): Capital Expenditures
$14.15M
Year ended 2025-12-31
$11.13M
Trailing 12 months to 2026-06-30
-25.3%
3-year compound annual growth
-4.4%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.15M | +41.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $10.03M | -58.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $24.36M | -28.1% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $33.90M | +8.6% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $31.22M | +76.6% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $17.68M | +195.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $5.98M | +222.2% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $1.86M | -23.5% | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | $2.43M | +78.3% | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | $1.36M | n/a | 2019-03-18, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $14.15M | +41.1% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $14.15M | -21.1% |
| Insmed Inc (INSM) | 2025-12-31 | $32.56M | +48.5% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $954.0K | -3.9% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $214.0K | +375.6% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $1.10M | +17.6% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $480.0K | +77.8% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $6.48M | -40.9% |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗